Iron Supplement

ApprovedSmall molecule

TThe University of Texas Health Science Center, Houston

Iron Supplement is one of 177 small molecule programs targeting Parasitic Infection. It is currently in Approved.

Indications

Total Trials

Active Trials

176

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parasitic InfectionActive, not recruiting

Weight LossActive, not recruiting

Oxidative StressActive, not recruiting

AnemiaActive, not recruiting

CirrhosisActive, not recruiting

GrowthActive, not recruiting

Parasitic InfectionApproved

Active, not recruiting

Weight LossApproved

Active, not recruiting

Oxidative StressPhase 2

Active, not recruiting

AnemiaPhase 2/Phase 3

Active, not recruiting

CirrhosisPreclinical

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Iron Supplement

TThe University of Texas Health Science Center, Houston

Approved

1 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

Glucophage

2 10

Glucagon

XXeris Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

HAE

NCT06624709

Clinical

Trials by Indication[1]

Weight loss1 trial

Lactoferrin Versus Iron Supplement in Irondeficiency Anemia and Weight Loss in Obese Children

Completed·—·Phase 4·NCT04014855·50 enrolled

Pregnancy1 trial

Oral Lactoferrin Versus Iron Supplementation During Pregnancy

Completed·SSouth Valley University·Phase 4·NCT03542825·300 enrolled

HAE1 trial

The Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution

Recruiting·RRiccardo Pfister·N/A·NCT06624709·160 enrolled

Oxidative Stress1 trial

Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients

Completed·—·Phase 2·NCT02335593·64 enrolled

Parasitic Infection1 trial

Parasitic Infection in Anemic Pregnant Women

Unknown status·—·Phase 4·NCT04391998·200 enrolled

7 more indications

Treatment1 trial

EXPLorative Data Collection for Patient chAracterIzation, treatmeNt Pathways and Outcomes of IRON Preparations

Completed·GGWT-TUD GmbH··NCT03382275·51 enrolled

Growth1 trial

to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Infants

Unknown status·DDeepanjan Bhattacharya·Phase 4·NCT03171324·300 enrolled

Cirrhosis1 trial

Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT04335058·130 enrolled

Lip1 trial

FLIPS: Ferfer Liposomal Iron Performance Study

Completed·PPharmEvo Pvt Ltd·Phase 4·NCT03112187·400 enrolled

Joint1 trial

Iron and Vitamin Adminstration Prior to Joint Replacement to Prevent Transfusion

Unknown status·MMeir Medical Center·N/A·NCT01676740·120 enrolled

Anemia1 trial

Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants

Completed·TThe University of Texas Health Science Center, Houston·Phase 2/3·NCT01224236·150 enrolled

Unspecified1 trial

Work and Iron Status Evaluation

Completed·NNational Institute on Aging (NIA)·N/A·NCT00094042·16,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Iron Supplement. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iron Supplement compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iron Supplement. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe University of Texas Health Science Center, Houston

Iron Supplement

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Weight loss1 trial

Pregnancy1 trial

HAE1 trial

Oxidative Stress1 trial

Parasitic Infection1 trial

Treatment1 trial

Growth1 trial

Cirrhosis1 trial

Lip1 trial

Joint1 trial

Anemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News